PNP Therapeutics, Inc.

PNP Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer treatments, particularly through its proprietary Gedeptin® technology designed to target tumor cells effectively. Established in 2000 in Birmingham, US, PNP Therapeutics, Inc. specializes in cancer therapeutics.

The firm has completed 3 deals, with the most recent funding round being Series B, raising USD 0. 67 mn from Greer Capital on May 14, 2012. The company is valued at USD 10. 017 mn.

PNP Therapeutics, Inc. is primarily focused on the development of Gedeptin®, a platform technology designed for cancer treatment. Gedeptin® operates by utilizing a proprietary approach that targets tumor cells, aiming to enhance therapeutic efficacy while minimizing harm to surrounding healthy tissues. The company’s technology has progressed through clinical trials, achieving Orphan Drug Status by the FDA, underscoring its potential in addressing rare cancer indications.

PNP Therapeutics primarily serves research institutions and pharmaceutical companies involved in oncology, with a geographical emphasis on critical regions like North America and Europe. PNP Therapeutics operates through a licensing model, having entered into an Assignment and License Agreement with GeoVax, Inc. , granting exclusive rights to its Gedeptin® technology. This agreement enables PNP to generate revenue through licensing fees and potential milestone payments associated with the advancement of Gedeptin® in clinical development.

Revenue transactions typically occur on a business-to-business basis with partners in the pharmaceutical industry and are structured to include upfront fees, royalties based on sales, and milestone payments tied to regulatory approvals or sales targets. The focus on Gedeptin® as a flagship product enhances potential revenue generation as it progresses through various stages of clinical and commercial development. In May 2012, PNP Therapeutics, Inc. raised USD 0.

67 mn in Series B funding from returning investor Greer Capital. The company is focused on expanding its reach in oncology by developing new therapeutic products utilizing the Gedeptin® technology. Plans for future growth include targeting new geographical markets in Europe and Asia by 2025, which are expected to significantly impact cancer treatment accessibility. The recent funding will support these initiatives, facilitating further clinical trials and partnerships necessary to advance their product offerings.